HDAC6-IN-82
HDAC6-IN-82 is a selective HDAC6 inhibitor with an IC50 of 4.9 nM against HDAC6. HDAC6-IN-82 inhibits HDAC1 (112 nM), HDAC2 (737 nM), HDAC3 (623 nM), HDAC8 (1140 nM), HDAC10 (91.4 nM) and HDAC11 (219 nM). HDAC6-IN-82 reduces cancer cell viability, induces cell cycle arrest, triggers apoptosis, and increases the acetylation levels of H3K9 and α-tubulin. HDAC6-IN-82 can be used in cancer-related research such as leukemia.
For research use only. We do not sell to patients.
- CAS No.: 1228571-33-2
- Formula: C22H23N3O3S
- Molecular Weight:409.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
HDAC6 4.9 nM (IC50) |
HDAC1 112 nM (IC50) |
HDAC2 737 nM (IC50) |
HDAC3 623 nM (IC50) |
HDAC4 71300 nM (IC50) |
HDAC5 14900 nM (IC50) |
HDAC7 NI nM (IC50) |
HDAC8 1140 nM (IC50) |
HDAC9 NI nM (IC50) |
HDAC10 33.1 nM (IC50) |
HDAC11 219 nM (IC50) |
In Vitro
HDAC6-IN-82 (Compound 14b) (48 h) reduces cell viability in a panel of human solid tumor and hematologic cancer cell lines, with the strongest potency against HL60 and U937 leukemia cells (CC50 = 1.2 μM and 1.3 μM)[1].
HDAC6-IN-82 (0.125-0.25 μM; 24-48 h) induces apoptosis in U937 acute myeloid leukemia cells in a time- and dose-dependent manner[1].
HDAC6-IN-82 (0.0675-0.25 μM; 48 h) inhibits nuclear and cytoplasmic HDAC activity in U937 acute myeloid leukemia cells[1].
Treatment of U937 acute myeloid leukemia cells with HDAC6-IN-82 (0.0675-0.25 μM; 48 h) modulates the mRNA expression of cell cycle and apoptosis regulators, upregulating p21, Bak and Bax while downregulating cyclin D1 and Bcl-2[1].
HDAC6-IN-82 (0.0675-0.25 μM; 48 h) regulates miRNA expression in U937 acute myeloid leukemia cells after 48 h of treatment, downregulating anti-apoptotic miRNAs involved in apoptosis regulation and upregulating pro-apoptotic miRNAs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:AML U937 cells
-
Concentration:0.125 and 0.25 μM
-
Incubation Time:24 h, 48 h
-
Result:Induced a time- and dose-dependent accumulation of cells in the sub-G1 phase: at 24 h, 0.125 μM caused ~30% sub-G1 cells and 0.25 μM caused ~40% sub-G1 cells; at 48 h, 0.125 μM caused ~45% sub-G1 cells and 0.25 μM caused ~70% sub-G1 cells.
Triggered a time- and dose-dependent increase in Annexin V-positive cells: at 24 h, 0.125 μM caused ~40% Annexin V-positive cells and 0.25 μM caused ~50% Annexin V-positive cells; at 48 h, 0.125 μM caused ~80% Annexin V-positive cells and 0.25 μM caused ~90% Annexin V-positive cells.
-
Cell Line:AML U937 cells
-
Concentration:0.0675, 0.125 and 0.25 μM
-
Incubation Time:48 h
-
Result:Induced hyperacetylation of histone H3K9 (fold changes relative to DMSO: 3.47 at 0.0675 μM, 5.23 at 0.125 μM, 3.51 at 0.25 μM) and α-tubulin (fold changes relative to DMSO: 3.5 at 0.0675 μM, 4.4 at 0.125 μM, 4.3 at 0.25 μM).
Upregulated the cyclin-dependent kinase inhibitor p21 (fold changes relative to DMSO: 11.1 at 0.0675 μM, 9.9 at 0.125 μM, 6.5 at 0.25 μM).
Downregulated cyclin D1 (fold changes relative to DMSO: 0.42 at 0.0675 μM, 0.53 at 0.125 μM, 0.37 at 0.25 μM).
-
Cell Line:AML U937 cells
-
Concentration:0.0675, 0.125 and 0.25 μM
-
Incubation Time:48 h
-
Result:Significantly upregulated mRNA levels of p21, pro-apoptotic Bak, and pro-apoptotic Bax across all tested concentrations.
Significantly downregulated mRNA levels of cyclin D1 and anti-apoptotic Bcl-2 across all tested concentrations.
SAHA showed no significant effect on Bak, Bax, or Bcl-2 mRNA levels.\nSignificantly downregulated anti-apoptotic miRNAs miR-17-5p, miR-18-5p, miR-20a-5p, miR-21-5p, and miR-22-3p across all tested concentrations, with effects stronger than SAHA for miR-18-5p and miR-22-3p.
Significantly upregulated pro-apoptotic miRNAs miR-122-5p, miR-769-5p, miR-181a-5p, and miR-181b-5p across all tested concentrations.
SAHA showed no significant effect on miR-122-5p or miR-181b-5p.
Chemical Information
-
CAS No. 1228571-33-2
-
Molecular Weight 409.50
-
Formula C22H23N3O3S
-
SMILES
O=C(CCCCCSC1=NC(C2=CC=C(C=C2)C3=CC=CC=C3)=CC(N1)=O)NO
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)